மீடியா மட்டும் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மீடியா மட்டும். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மீடியா மட்டும் Today - Breaking & Trending Today

Icosavax Announces Closing of Initial Public Offering and


Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 02, 2021 16:01 ET
| Source:
Icosavax, Inc.
Icosavax, Inc.
Seattle, Washington, UNITED STATES
SEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced the closing of its initial public offering of 13,953,332 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,819,999 additional shares, at an initial public offering price of $15.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payabl ....

New York , United States , South Korea , Riverside Plaza , Jessica Yingling , Laurence Watts , William Blair , Broadridge Financial Solutions , Institute For Protein Design , Little Dog Communications Inc , Exchange Commission , William Blair Company , Prospectus Department , Icosavax Inc , University Of Washington , Equity Syndicate Prospectus Department , Gilmartin Group , Evercore Group , Nasdaq Global Select Market , Island Avenue , Equity Capital Markets , Protein Design , North America , Media Only , Investor Contact , புதியது யார்க் ,

Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose


Press release content from Business Wire. The AP news staff was not involved in its creation.
Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose
July 20, 2021 GMT
REDWOOD CITY, Calif. (BUSINESS WIRE) Jul 19, 2021
Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the release of preclinical data in nonhuman primates (NHPs) of the company’s intranasal recombinant live attenuated COVID-19 vaccine (MV-014-212). The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines. Furthermore, the data show that MV-014-212 stimulates mucosal (nasal IgA) antibodies in the upper respiratory tract, the major infection route for SARS-CoV-2, and systemic (serum neutralizin ....

South Africa , United States , United Kingdom , Redwood City , Roderick Tang , Jessica Yingling , Martin Moore , Mariana Tioni , Bill Daly , Meissa Attenublock , Emory University , Little Dog Communications , Chief Scientific Officer , Meissa Contacts , Clinical Trials , Chief Business Officer , Meissa Vaccines , Media Only , Business Wire , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ரெட்வுட் நகரம் , ரோடெரிக் டாங் , ஜெசிகா யிங்லிங் , மார்டின் மூர் , ர சி து டேலி ,